Tag Archives: Best Supportive Care (BSC)

Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer’s Disease (Health Technology Assessment)

[A version of this item appears in: Dementia: the Latest Evidence Newsletter (RWHT), Volume 2 Issue 11, June 2012]. Summary The purpose of this Health Technology Assessment was to review and update guidance to the NHS in England and Wales … Continue reading

Posted in Acute Hospitals, Community Care, For Doctors (mostly), For Researchers (mostly), Management of Condition, National, NHS, NIHR, Pharmacological Treatments, Proposed for Next Newsletter, Systematic Reviews, UK | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment